Plain-English translation of NCT05288205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing two new medications called and given together to treat advanced cancers (like lung, colon, or pancreatic cancer) that have a specific genetic mutation called KRAS p.G12C. The trial will first figure out the safest dose of this medication combination, then test whether it actually shrinks tumors in patients who have already tried standard treatments or cannot tolerate them.
Many people with advanced cancers that carry the KRAS p.G12C mutation don't respond well to available treatments, or the treatments stop working. Researchers believe this new medication combination may offer hope for patients who have limited options.
You likely qualify if…
You likely don't qualify if…
You will take the two study medications by mouth, likely as daily pills. The trial has two phases: first, researchers will gradually increase doses in a small group to find the safest dose, then a larger group will receive that dose to test how well it works. You will have regular clinic visits for blood tests, imaging scans to measure your tumors, and check-ups to monitor for side effects. The trial is recruiting up to 240 participants across multiple medical centers.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China